Myung-Ju Ahn
Myung-Ju Ahn is one of Asia's most prolific lung cancer trialists, a steady presence on the steering committees of the EGFR, ALK, and immunotherapy trials that set today's standards.
Myung-Ju Ahn leads thoracic medical oncology at Samsung Medical Center and has been a principal or co-investigator on many of the pivotal NSCLC trials of the last decade, including osimertinib, lorlatinib, and checkpoint-inhibitor studies with large Korean enrolment. Her work spans EGFR resistance, ALK inhibitors, and head-and-neck immunotherapy.
Pages like this
not linked directly; found by shared links- CancerSmall-cell lung cancer
Shares DeLLphi-301: tarlatamab, a DLL3-targeting T-cell engager, in previously treated small-cell lung cancer, Osimertinib and the tag lung.
- PersonBenjamin Solomon
Shares CROWN, Lorlatinib, ALK, Non-small-cell lung cancer.
- PairingSequence: targeted therapy before immunotherapy in driver-positive NSCLC
Shares CROWN, Lorlatinib, ALK, Osimertinib.
- PersonEnriqueta Felip
Shares DeLLphi-301: tarlatamab, a DLL3-targeting T-cell engager, in previously treated small-cell lung cancer, ALK, Osimertinib, EGFR.
- TrialLAURA
Shares Osimertinib, EGFR, Non-small-cell lung cancer.
- InstitutionShanghai Chest Hospital
Shares Lorlatinib, ALK, Osimertinib, EGFR.
- PersonJohn V. Heymach
Shares Osimertinib, EGFR, Head and neck squamous cell carcinoma, Non-small-cell lung cancer.
- PersonJustin F. Gainor
Shares Lorlatinib, ALK, Non-small-cell lung cancer.